Navigation Links
Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
Date:4/2/2009

-- European Commission grants marketing authorization for Intercell's IXIARO, the first licensed vaccine against Japanese Encephalitis for travelers and military personnel in Europe

-- This final decision follows the positive opinion from European Committee for Human Medicinal Products (CHMP) in December 2008

VIENNA, April 2 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that its new vaccine to prevent Japanese Encephalitis, IXIARO(R), has been approved by the European Commission. The approval by the European Union, the first for a vaccine to prevent the disease, provides formal market authorization in all 27 member states as well as Norway and Iceland.

"The European approval of IXIARO marks a crucial milestone in Intercell's evolution as one of the leading independent vaccine development companies with a vaccine marketed," said Intercell's Chief Executive Officer Gerd Zettlmeissl. "For the first time, both civilians and members of the military across Europe will have access to a safe and effective vaccine against this devastating and endemic disease found throughout Asia, which kills as many as one in three of the people it strikes."

This decision follows the positive opinion from European Committee for Human Medicinal Products (CHMP) in December 2008. Novartis AG holds marketing and distribution rights for IXIARO, in the United States, Europe, Japan, Korea and certain other markets in Asia and Latin America.

A final assessment by the European COMP (Committee for Orphan Medicinal Products) focused on updated information indicating that the expected potential European vaccine market for IXIARO is significantly higher than initially evaluated, and, therefore, the vaccine will not have an orphan drug designation.

Intercell's product is a purified, inactivated vaccine for active immunization against infections with Japanese Encephalitis virus. The new vaccine is manufactured in Intercell's proprietary manufacturing facility in Scotland and is prepared using tissue culture rather than live organisms.

In addition to the European approval, Intercell's vaccine was also approved by the Australian Therapeutic Goods Administration (TGA) for use in Australia, and the U.S. Food and Drug Administration for the U.S. market.

About Japanese Encephalitis

Japanese Encephalitis is a mosquito-borne infection that strikes 30,000 to 50,000 individuals a year, causing 10,000 to 15,000 deaths (both probably an underestimate due to underreporting and other factors). Up to 50 percent of survivors have persistent neurological sequelae. Japanese Encephalitis is the leading cause of viral neurological disease and disability in Asia and the most important viral encephalitis in Asia. The disease is most common in several developing countries in Asia, including India and China. As there is no specific treatment for JE, health care experts recommend vaccination as the only highly effective protection for the millions of travelers and military personnel who live in or travel to areas where the virus circulates.

About IXIARO

Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization against the Japanese Encephalitis virus. The total development time of this vaccine took more than 10 years. The vaccine was developed under a Collaborative Research and Development Agreement with the Walter Reed Army Institute of Research, a biomedical research laboratory for the U.S. Department of Defense.

Intercell's Phase III trials for the vaccine found that the vaccine demonstrated excellent immunogenicity against Japanese Encephalitis and an overall clinical safety profile similar to placebo, combined with an excellent local tolerability profile. These data were published in The Lancet in December 2007:

  • The immunogenicity was comparable to that of the U.S. licensed product, JE-VAX(R).
  • Intercell's vaccine demonstrated an overall clinical safety profile similar to placebo.
  • Further, Intercell's Japanese Encephalitis vaccine had a more favorable local tolerability profile in the head-to-head study with JE-VAX(R).

About Intercell AG

Intercell AG is an innovative biotechnology company that designs and develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the company's first product on the market.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin and the Statens Serum Institut.

The Company's development pipeline includes Phase II vaccine programs for Pseudomonas (in-house development) and S. aureus, which is being developed with Merck & Co. Inc. The Company's novel Travelers' Diarrhea vaccine patch will enter Phase III testing in 2009. Intercell is also in clinical trials of a vaccine enhancement patch with injected Pandemic Influenza vaccines (one shot plus patch). In addition, four other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


'/>"/>
SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
2. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
3. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
4. Iomai Stockholders Approve Merger With Intercell Subsidiary
5. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
6. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
7. China Biologic Products Announces Strong 2008 Results
8. Senetek PLC Announces New Investor Communication Hotline
9. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
10. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
11. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced its ... tumors to grow on nerves throughout the body. It affects 1 in 3,000 people ... events held during the month of May, as well as online activities, Neurofibromatosis Awareness ...
(Date:5/4/2016)... 2016 According to a new ... - Global Industry Analysis, Size, Share, Growth, Trends, and ... to expand at a CAGR of 17.1% from 2016 ... Metabolomics is the extensive study of small ... or organisms. Together, these small molecules and their interactions ...
(Date:5/4/2016)... ... ... PBI-Gordon Corporation is pleased to announce Doug Obermann has been promoted to ... PBI-Gordon in February 1988, after finishing his masters in agronomy from Iowa State University. ... to national product manager, to helping develop, name and launch many of the most ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... has leveraged recent innovations in biotechnology to help treat hormonal and stress related ... loss, Nutrafol® has captured the hearts of key opinion leaders in the medical ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):